Hematology

The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed new follow-up data from the HOPE-B study presented at ASH 2022.

Review top news and interview highlights from the week ending December 16, 2022.

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed updated data presented at the ASH 2022 meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

New data from a phase 1/2 trial of BMS-986393 were presented at the 64th Annual ASH Meeting.

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed unmet needs in acute myeloid leukemia and how UCART123v1.2 may address these.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed new data from a phase 1/2 trial presented at ASH 2022.

Annualized bleed rate and FVIII infusion rates significantly decreased after infusion with the gene therapy.

Four of 17 patients who received UCART123v1.2 showed clinical benefit.

The professor at University Hospital Dresden discussed data presented at the 2022 ASH meeting.

The complete metabolic response rate was 70% 3 months after infusion.

The study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape.

100% of patients who achieved transfusion independence reported an overall benefit from treatment.

Rates of complete response to the novel CAR-T varied from 67% to 75% across the 4 dosage levels tested.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed the session she moderated at the ASH 2022 annual meeting.

Among the 38 patients now dosed and evaluable, the ORR remains at 100%.

A complete response rate of 67% was reported and no treatment-limiting toxicity occurred.

A DCE analysis weighed gender-, age-, and disease-severity-specific annual costs as opposed to traditional cost-effectiveness models.

Additional data on 2 patients who developed persistent anemia suggests a genetic cause may be behind the serious adverse event.

The patient tolerated administration of Mylotarg after engraftment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The first 2 participants dosed are free of vaso-occlusive events as of 5 and 1.5 months of follow-up after treatment with EDIT-301.

Ivan Horak, MD, discussed Tessa’s cell therapy platforms and the ACTION clinical trial.

Patients with non-Hodgkin lymphoma in Nkarta's phase 1 study had a 75% complete response rate.

The associate professor from the Medical College of Wisconsin discussed how to address unmet needs with CAR T-cell therapies.